WHO ICTRP trial
Study on the safety, completion rate and immunology of isoniazid-rifapentine…
ChiCTR2200067180 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200067180 |
|---|---|
| Public title | Study on the safety, completion rate and immunology of isoniazid-rifapentine combined with Mycobacterium vaccae (HPMV regimen) in the preventive treatment of latent tuberculosis infection for 28 days |
| Scientific title | Study on the safety, completion rate and immunology of HPMV regimen in the preventive treatment of latent tuberculosis infection |
| Primary sponsor | The Third People’s Hospital of Shenzhen |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | Latent tuberculosis infection |
| Interventions | HPMV regimen treatment group:Isoniazid-Rifapentine plus Mycobacterium vaccae(HPMV regimen) prophylactic anti-tuberculosis therapy for 28 days. |
| Registration date | Dec 28, 2022 |
| Target size | HPMV regimen treatment group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: